Brief: MAIA Biotechnology Says Telomere-Targeting Agent THIO Demonstrated Significantly Greater Tumor Inhibition
13/02/2023 13:55
Feb 13 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY’S TELOMERE-TARGETING AGENT THIO, IN
COMBINATION WITH CHECKPOINT INHIBITOR IMMUNE THERAPIES
ATEZOLIZUMAB (ANTI-PD-L1) OR PEMBROLIZUMAB (ANTI-PD-1),
DEMONSTRATED SIGNIFICANTLY GREATER TUMOR INHIBITION
Source text for Eikon: ID:nBw1lytjza
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale